In addition, Sequanta Technologies offers 10x Genomics Visium spatial transcriptomics solutions, including the high-resolution Visium HD platform. Powered by patented spatial barcode technology, these solutions are compatible with both fresh-frozen and FFPE tissue sections, enabling in situ mapping of whole-transcriptome expression while preserving tissue morphology and accurately localizing gene expression within tissue sections. By integrating single-cell sequencing and spatial transcriptomics technologies, researchers can not only resolve molecular characteristics of distinct cell populations but also reconstruct their spatial distribution and cellular interactions within tissue microenvironments. This integrated approach provides comprehensive insights into biological mechanisms by combining molecular profiling with spatial context, supporting advanced clinical and translational research.

Sequanta Technologies has extensive experience in single-cell sequencing and optimized sample processing workflows across a broad range of mouse and rat models. Our expertise covers PBMCs, T/B cells, liver (cell isolation and nuclei extraction), spleen, brain (cell isolation and nuclei extraction), lung, small intestine, thyroid, embryonic tissues, hypothalamus, brainstem, adrenal gland, bone tissues (femur/tibia), organoids, subcutaneous tumors, colon cancer, colorectal cancer, bladder cancer, and other complex samples. Our capabilities include processing fresh tissues, cryopreserved tissues, and challenging tissue samples requiring specialized nuclei extraction strategies, covering PDX models and diverse tumor model mice.

For human samples, Sequanta Technologies has accumulated extensive experience in processing PBMCs, T/B cells, bone marrow, and tumor tissues, including lung cancer, esophageal cancer, gastric cancer, liver cancer, colorectal cancer, head and neck squamous cell carcinoma, breast cancer, pancreatic cancer, glioma, osteosarcoma, prostate cancer, oral and maxillofacial tumors, lung cancer PDX samples, pancreatic cancer renal metastases, metastatic lymph nodes, iris, oral mucosa, thyroid, kidney, and other tissues. The workflow covers primary tumors, metastatic lesions, biopsy samples, and surgical specimens, with expertise in optimizing dissociation and nuclei extraction protocols for low-viability, highly fibrotic, and other challenging tissues.

scRNA-seq enables unbiased identification and clustering of cell subsets based on gene expression profiles from individual cells. By integrating bioinformatics analysis, reference databases, and marker gene signatures, scRNA-seq can decipher the cellular composition of the tumor microenvironment and reveal the functional states of different cell populations.